

Petition

To the Legislative Assembly of Ontario:

WHEREAS Systemic Lupus Erythematosus (Lupus or SLE) is a complex, chronic, debilitating autoimmune disease that can cause major organ damage, including to the heart, lungs, kidney and brain and cannot currently be cured;

WHEREAS Lupus affects an estimated 40,000 Ontarians, predominantly women and people of colour; WHEREAS Lupus affects each lupus patient differently and any one medication/treatment cannot be relied upon to control the disease and/or improve quality of life;

WHEREAS Many lupus-specific biologics, including Anifrolumab and Belimumab for Lupus Nephritis (LN) and SLE, used to manage Lupus have not been added to the Ontario Drug Formulary or have been added but only under the Exceptional Access Program (EAP);

WHEREAS Many more lupus-specific biologics are in the pipeline and are expected to be available in the near future; and

WHEREAS Average time for EAP approval is 3-5 weeks and creates an unnecessary administrative burden on Rheumatologists who are already resource constrained.

We the undersigned petition the Legislative Assembly of Ontario as follows:

 To support and endorse the listing of all current and new lupus-specific biologics approved by CADTH, including Anifrolumab and Belimumab for LN and SLE, on the Ontario Drug Formulary under the "Limited Use" code;

You must be a resident of Ontario to sign this petition.

Name (printed)	Address (printed)	Signature